International Stem Cell Stock

International Stem Cell EBIT Margin

The EBIT Margin (Operating Margin) of International Stem Cell (ISCO) as of Aug 4, 2026 is -2.93 %. In the previous year, EBIT Margin (Operating Margin) was -0.75 % — a change of 292.00% (lower).

EBIT Margin

-2.93 %

YoY

292.00%

Last updated:

EBIT Margin (Operating Margin) of International Stem Cell is 2026 -2.93 % . EBIT Margin (Operating Margin) of International Stem Cell was 2025 -0.75 % . It decreases by 292.00% lower compared to the previous year.

For International Stem Cell, the operating (EBIT) margin of -2.9% is up versus -23.3% a few years ago.

Access this data via the Eulerpool API

International Stem Cell Stock analysis

What does International Stem Cell do? International Stem Cell Corp (ISCO) is a biotechnology company founded in 2005 and headquartered in Carlsbad, California. It specializes in the development and manufacture of stem cell products for therapeutics and research purposes. ISCO specializes in the production of "human parthenogenetic stem cells" (hpSCs). This means that they produce stem cells from human egg cells that can replicate without fertilization by sperm. The company is a leader in this field and has filed over 80 patents worldwide. ISCO has various business areas, including life science research, therapeutics, dermatology, and animal health. The company partners with various industries, including academic institutions, pharmaceutical and biotechnology companies, and government agencies. One of their biggest partnerships is with the Chinese company Sino Biopharmaceuticals. ISCO offers a variety of products, including in vitro diagnostics for testing genetic diseases such as Huntington's and food allergies. However, the diagnostics division of the company is a small department primarily focused on research and development purposes. ISCO also has a dermatology division called Lifeline Skin Care, which manufactures skincare products based on human stem cells. These products have been developed for improving skin texture and reducing scars. Lifeline Skin Care is a luxury brand for skincare products currently sold in over 15 countries worldwide. In terms of animal health, ISCO recently launched a new division called Lifeline Animal Health. They are developing animal therapeutics based on hpSCs. The company has already developed the first animal therapeutic for dogs approved for the treatment of hip dysplasia. However, ISCO primarily focuses on the development of therapeutics for human stem cells. The company aims to be a global leader in the development of stem cell therapeutics. Their first product, CytoCor for heart disease, is already in clinical phase 1b/2a. The drug is intended to help reduce damage after a heart attack and improve heart function. ISCO also plans to develop therapeutics for other indications, including Alzheimer's disease, based on hpSCs. The company has a strong partnership with the California Institute for Regenerative Medicine, which focuses on stem cell research and their use in medicine. ISCO is a leading company in stem cell research and development. They have a unique approach to stem cell production and offer a variety of products and services for various industries. The company aims to develop groundbreaking stem cell therapeutics and change the way diseases are treated. International Stem Cell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about International Stem Cell stock

EBIT Margin (Operating Margin) of International Stem Cell is -2.93 % in 2026.

EBIT Margin (Operating Margin) of International Stem Cell changed from -0.75 % to -2.93 %, representing a 292.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) International Stem Cell since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s International Stem Cell with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

Margins — International Stem Cell

All Key Metrics — International Stem Cell